Effects of Stoss Therapy of Vitamin D3 on Peri-operative Outcomes in Patients Receiving General Surgery
Primary Purpose
Vitamin D Deficiency, Surgery
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Vitamin D3
95% MCT
Sponsored by
About this trial
This is an interventional treatment trial for Vitamin D Deficiency
Eligibility Criteria
Inclusion Criteria: 20 years or older Adult patients who will receive general surgery Exclusion Criteria: Chronic liver diseases Hypercalcemia Using estrogen drug, bisphosphonate, other durgs to treat bone diseases Sarcoidosis, Multiple myeloma or Primary hyperparathyroidism Pregnant women Other trial participation
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Vitamin D3
Control group
Arm Description
The experimental group will receive 576000 IU in single oral dose of liquid vitamin D3~7 days prior to the surgery.
The control group will receive 95% MCT D3~7 days prior to the surgery.
Outcomes
Primary Outcome Measures
Mortality rate
Secondary Outcome Measures
Full Information
NCT ID
NCT05650268
First Posted
July 26, 2021
Last Updated
December 13, 2022
Sponsor
National Taiwan University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05650268
Brief Title
Effects of Stoss Therapy of Vitamin D3 on Peri-operative Outcomes in Patients Receiving General Surgery
Official Title
Effects of Stoss Therapy of Vitamin D3 on Peri-operative Outcomes in Patients Receiving General Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Because of impact from COVID-19 pandemic
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
April 1, 2022 (Actual)
Study Completion Date
April 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Taiwan University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To investigate whether preoperative supplement with high-dose vitamin D3 can reduce the perioperative risk and enhance recovery
Detailed Description
Perioperative management for risk reduction in patients undergoing major surgery are taken increasingly important nowadays. The patient factor (age and comorbidities mainly), type of surgery and extent of tissue injury are major contributions to the development perioperative complications. From nutrition support to nutrition therapy, a comprehensive nutrition plays a pivotal role to optimize the above three key factors and hence reduce the perioperative risk. Vitamin D, a pleiotropic hormone with extensive physiological effect, is one of the nutrients critical to perioperative outcomes. It not only meets the essential demand of surgical patients, such as wound care, infection control, metabolic support and organ support, but also attenuates oxidative stress, modulates dys-inflammation and repair the damaged organelles like telomere and mitochondria. This is a double-blind, randomized controlled trial in a single center. Sixty eligible adult patients who will undergo general surgery are to be included.
The experimental group will receive 576000 IU in single oral dose of liquid vitamin D 3~7 days prior to the surgery. The primary endpoint is rapid recovery index, such as bowel recovery, pain control, sedation and fatigue assessment. The secondary endpoints include perioperative inflammatory indexes, hemodynamic parameters, glycemic control as well as safety evaluation of vitamin D.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency, Surgery
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vitamin D3
Arm Type
Experimental
Arm Description
The experimental group will receive 576000 IU in single oral dose of liquid vitamin D3~7 days prior to the surgery.
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
The control group will receive 95% MCT D3~7 days prior to the surgery.
Intervention Type
Drug
Intervention Name(s)
Vitamin D3
Other Intervention Name(s)
Vitamin D
Intervention Description
Receiving 576000 international units in single oral dose of liquid vitamin D 3~7 days prior to the surgery.
Intervention Type
Other
Intervention Name(s)
95% MCT
Intervention Description
95% MCT supplement 3-7 day before surgery
Primary Outcome Measure Information:
Title
Mortality rate
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
20 years or older
Adult patients who will receive general surgery
Exclusion Criteria:
Chronic liver diseases
Hypercalcemia
Using estrogen drug, bisphosphonate, other durgs to treat bone diseases
Sarcoidosis, Multiple myeloma or Primary hyperparathyroidism
Pregnant women
Other trial participation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yin-Yi Han, MD,PhD
Organizational Affiliation
National Taiwan University Hospital
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effects of Stoss Therapy of Vitamin D3 on Peri-operative Outcomes in Patients Receiving General Surgery
We'll reach out to this number within 24 hrs